Multiphoton imaging of cytotoxic T lymphocyte-mediated antitumor immune responses

Current Topics in Microbiology and Immunology

Volumn 334, Issue 1, 2009, Pages 265-287

  Boissonnas, Alexandre ^a   Scholer Dahire, Alix ^a   Fetler, Luc ^b   Amigorena, Sebastian ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPHOTON MICROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; THREE DIMENSIONAL IMAGING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; ANIMAL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; INSTRUMENTATION; METHODOLOGY; MOUSE; PATHOLOGY; THYMOMA;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MICE; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; THYMUS NEOPLASMS;

EID: 69449092250     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-93864-4_11     Document Type: Review

References (90)

1. Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, Germain RN. (2006) Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25:989-1001
2. Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA. (1991) Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173:647-658
3. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. (2006) Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 36:468-477
4. Boissonnas A, Combadiere C, Lavergne E, Maho M, Blanc C, Debre P, Combadiere B. (2004) Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 173:222-229
5. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. (2007) In vivo imaging of cyto-toxic T cell infiltration and elimination of a solid tumor. J Exp Med 204:345-356
6. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Kissenpfennig A, Sparwasser T, Malissen B, Fetler L, Amigorena S. Regulatory T cells control dendritic cells survival in tumor draining lymph node. (Submitted)
7. Bonmort M, Ullrich E, Mignot G, Jacobs B, Chaput N, Zitvogel L. (2007) Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). Biochimie 89:872-877
8. Bousso P. (2008) T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol 9:155-165
9. Breart B, Lemaitre F, Celli S, Bousso P. (2008) Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 118:1390-1397
10. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108
11. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. (1999) Lymphocyte trafficking and regional immunity. Adv Immunol 72:209-253
12. Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, Walker PR. (2003) Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 171:2187-2191
13. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Ruegg C, Dietrich PY, Walker PR. (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22:175-184
14. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. (2006) Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440:890-895
15. Celli S, Lemaitre F, Bousso P. (2007) Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 27:625-634
16. Chen Q, Wang WC, Evans SS. (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52:670-679
17. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K. (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci \USA 102:419-424
18. Christinck ER, Luscher MA, Barber BH, Williams DB. (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352:67-70
19. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22:371-383
20. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC, Wagstaff J, Griffioen AW. (2003) Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63:2322-2329
21. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW. (2004) Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 64:406-414
22. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. (2006a) Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 177:6018-6024
23. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. (2006b) Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 176:1447-1455
24. Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, Gambhir SS, Witte ON. (2003) Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci \USA 100:1232-1237
25. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591-1602
26. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, et al. (2005) Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65:9080-9088
27. Gajewski TF, Meng Y, Harlin H. (2006) Immune suppression in the tumor microenvironment. J Immunother 29:233-240
28. Garcia Z, Pradelli E, Celli S, Beuneu H, Simon A, Bousso P. (2007) Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc Natl Acad Sci \USA 104:4553-4558
29. Hellstrom KE, Hellstrom I, Chen L. (1995) Can co-stimulated tumor immunity be therapeutically efficacious. Immunol Rev 145:123-145
30. Hollenbaugh JA, Dutton RW. (2006) IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 177:3004-3011
31. Hollenbaugh JA, Reome J, Dobrzanski M, and Dutton RW. (2004) The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 173:1738-1743
32. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. (1996a) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo. J Exp Med 183:769-776
33. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. (1996b) In vivo cross-priming of MHC classI-restricted antigens requires the TAP transporter. Immunity 4:349-355
34. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. (2004) Distinct T cell dynamicsin lymph nodes during the induction of tolerance and immunity. Nat Immunol 5:1235-1242
35. Hugues S, Boissonnas A, Amigorena S, Fetler L. (2006) The dynamics of dendritic cell-T cellinteractions in priming and tolerance. Curr Opin Immunol 18:491-495
36. Hugues S, Scholer A, Boissonnas A, Nussbaum A, Combadiere C, Amigorena S, Fetler L. (2007)Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. NatImmunol 8:921-930
37. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. (2001) Tumor rejection by disturbing tumorstroma cell interactions. J Exp Med 194:1549-1559
38. Jain RK, Koenig GC, Dellian M, Fukumura D, Munn LL, Melder RJ. (1996) Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 15:195-204
39. Jain RK, Munn LL, Fukumura D. (2002) Dissecting tumour pathophysiology using intravitalmicroscopy. Nat Rev Cancer 2:266-276
40. Joncker NT, Helft J, Jacquet A, Premel V, Lantz O. (2006a) Intratumor CD4 T-cell accumulationrequires stronger priming than for expansion and lymphokine secretion. Cancer Res66:5443-5451
41. Joncker NT, Marloie MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J, Sigal-Zafrani B,Vincent-Salomon A, Sastre X, Lantz O. (2006b) Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer118:1205-1214
42. Kammertoens T, Schuler T, Blankenstein T. (2005) Immunotherapy: target the stroma to hit thetumor. Trends Mol Med 11:225-231
43. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. (2003) Invivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocytetrafficking to tumors. Cancer Res 63:6838-6846
44. Klein E, Klein G. (1972) Specificity of homograft rejection in vivo, assessed by inoculation ofartificially mixed compatible and imcompatible tumor cells. Cell Immunol 5:201-208
45. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A , Kuhlcke K ,Ohashi PS, Hengartner H, et al. (1995) Fibroblasts as efficient antigen-presenting cells inlymphoid organs. Science 268:1343-1347
46. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T. (2005)Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanomapatient vaccinated with a MAGE tumor antigen. J Exp Med 201:249-257
47. Mantovani A, Allavena P, Sica A, Balkwill F. (2008) Cancer-related inflammation. Nature454:436-444
48. Maric M, Zheng P, Sarma S, Guo Y, Liu Y. (1998) Maturation of cytotoxic T lymphocytes againsta B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumorand host antigen-presenting cells. Cancer Res 58:3376-3384
49. Mempel TR, Henrickson SE, Von Andrian UH. (2004) T-cell priming by dendritic cells in lymphnodes occurs in three distinct phases. Nature 427:154-159
50. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH.(2006) Regulatory T cells reversibly suppress cytotoxic T cell function independent of effectordifferentiation. Immunity 25:129-141
51. Miller MJ, Safrina O, Parker I, Cahalan MD (2004) Imaging the single cell dynamics of CD4+ Tcell activation by dendritic cells in lymph nodes. J Exp Med 200:847-856
52. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH.(2003) Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature424:88-93
53. Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH,Ertl HC, Haydon PG, Weninger W. (2006) Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 203:2749-2761
54. Mrass P, Weninger W. (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 213:195-212
55. Mukai S, Kjaergaard J, Shu S, Plautz GE. (1999) Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 59:5245-5249
56. Nagaraj S, Gabrilovich DI. (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561-2563
57. Ng LG, Mrass P, Kinjyo I, Reiner SL, Weninger W. (2008) Two-photon imaging of effector T-cell behavior: lessons from a tumor model. Immunol Rev 221:147-162
58. Nimmerjahn F, Ravetch JV. (2007) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239-245
59. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96:2233-2238
60. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-1064
61. Pawelec G, Koch S, Griesemann H, Rehbein A, Hahnel K, Gouttefangeas C. (2006) Immunosenescence, suppression and tumour progression. Cancer Immunol Immunother 55:981-986
62. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. (2000) T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 165:7116-7124
63. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109:5346-5354
64. Qin Z, Blankenstein T. (2000) CD4+ T cell-mediated tumor rejection involves inhibition of ang-iogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686
65. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308
66. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543
67. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. (2008) Intercellular Adhesion Molecule-1-Dependent Stable Interactions between T Cells and Dendritic Cells Determine CD8(+) T Cell Memory. Immunity 28:258-270
68. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. (1998) How do cytotoxic lymphocytes kill their targets. Curr Opin Immunol 10:581-587
69. Skokos D, Shakhar G, Varma R, Waite JC, Cameron TO, Lindquist RL, Schwickert T, Nussenzweig MC, Dustin ML. (2007) Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat Immunol 8:835-844
70. Smirnov P, Lavergne E, Gazeau F, Lewin M, Boissonnas A, Doan BT, Gillet B, Combadiere C, Combadiere B, Clement O. (2006) In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn Reson Med 56:498-508
71. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, et al. (2002) Inhibition of cytolytic T lymphocyte proliferation by autolo-gous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267-5272
72. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. (2002) Increasing tumor antigen expression overcomes "ignorance" to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity 17:737-747
73. Spiotto MT, Rowley DA, Schreiber H. (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10:294-298
74. Stevanovic S. (2002) Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2:514-520
75. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15:751-761
76. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832
77. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, Lafaille JJ, Dustin ML. (2006) Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 203:505-511
78. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. (2006) Visualizing regulatory T cell control of autoimmune responses in non-obese diabetic mice. Nat Immunol 7:83-92
79. Townsend SE, Allison JP. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370
80. Tumeh PC, Radu CG, Ribas A. (2008) PET imaging of cancer immunotherapy. J Nucl Med 49:865-868
81. Valitutti S, Muller S, Dessing M, Lanzavecchia A. (1996) Different responses are elicited in cyto-toxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183:1917-1921
82. Vignali DA, Collison LW, Workman CJ. (2008) How regulatory T cells work. Nat Rev Immunol 8:523-532
83. Weissman IL. (1973) Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact. J Natl Cancer Inst 51:443-448
84. Wiedemann A, Depoil D, Faroudi M, Valitutti S. (2006) Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci USA 103:10985-10990
85. Winter H, Hu HM, Urba WJ, Fox BA. (1999) Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand. (APO-1L/CD95L) J Immunol 163:4462-4472
86. Wolf K, Muller R, Borgmann S, Brocker EB, Friedl P. (2003) Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 102:3262-3269
87. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276
88. Yang G, Hellstrom KE, Chen L. (1997) The role of B7-2. (CD86) in tumour immunity. Expert Opin Investig Drugs 6:677-684
89. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779-791
90. Zinkernagel RM. (2002) On cross-priming of MHC class I-specific CTL: rule or exception. Eur J Immunol 32:2385-2392